|
|
 Previous Article | Table of Contents | Next Article 
Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates
with a shift towards a lymphoblastoid phenotype
MH Falk, BC Trauth, KM Debatin, C Klas, CD Gregory, AB Rickinson, A Calender, GM Lenoir, JW Ellwart and PH Krammer
Institut fur Klinische Molekularbiologie und Tumorgenetik, GSF, Munchen,
Germany.
APO-1 is a cell surface molecule that induces apoptosis when ligated with
the monoclonal antibody anti-APO-1. Expression of APO-1 and response to
anti-APO-1 was investigated in a number of Epstein-Barr virus
(EBV)-positive and -negative Burkitt lymphoma (BL) cell lines, in
EBV-immortalized lymphoblastoid cell lines, and in cells from fresh BL
biopsies. APO-1 was not expressed in EBV-negative cell lines and in EBV-
positive BL cell lines with a phenotype corresponding to BL tumor biopsy
cells (CD10+, CD21-, CD23-, CD30-, CD39-, CDw70-, CD77+). Accordingly,
fresh BL cells obtained from three BL biopsies were APO-1 negative.
EBV-positive BL cell lines that had acquired a lymphoblastoid phenotype
(CD10-, CD21+, CD23+, CD30+, CD39+, CDw70+, CD77-) upon prolonged in vitro
cultivation, as well as normal B-lymphoblastoid cell lines, expressed a
high density of APO-1. APO-1 may, therefore, be regarded as a B-cell
activation marker. APO-1 expression is not the only prerequisite for
anti-APO-1-induced apoptosis because 6 of 7 APO-1- expressing EBV-positive
BL cell lines were not sensitive to anti-APO-1, whereas all lymphoblastoid
cell lines were killed by anti-APO-1. The sensitivity of lymphoblastoid
cell lines to anti-APO-1-mediated apoptosis may open a new therapeutic
approach for the treatment of EBV- induced lymphoproliferative lesions in
immunocompromised individuals, because these are composed of cells with a
lymphoblastoid phenotype.
Volume 79,
Issue 12,
pp. 3300-3306,
06/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Le Clorennec, T.-S. Ouk, I. Youlyouz-Marfak, S. Panteix, C.-C. Martin, J. Rastelli, E. Adriaenssens, U. Zimber-Strobl, J. Coll, J. Feuillard, et al.
Molecular Basis of Cytotoxicity of Epstein-Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) in EBV Latency III B Cells: LMP1 Induces Type II Ligand-Independent Autoactivation of CD95/Fas with Caspase 8-Mediated Apoptosis
J. Virol.,
July 1, 2008;
82(13):
6721 - 6733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Snow, S. L. Lambert, Y. Natkunam, C. O. Esquivel, S. M. Krams, and O. M. Martinez
EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis.
J. Immunol.,
September 1, 2006;
177(5):
3283 - 3293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Le Clorennec, I. Youlyouz-Marfak, E. Adriaenssens, J. Coll, G. W. Bornkamm, and J. Feuillard
EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-{kappa}B, STAT1, and p53
Blood,
March 1, 2006;
107(5):
2070 - 2078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Goodyear and G. J. Silverman
Death by a B Cell Superantigen: In Vivo VH-targeted Apoptotic Supraclonal B Cell Deletion by a Staphylococcal Toxin
J. Exp. Med.,
May 5, 2003;
197(9):
1125 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Marcato, G. Mulvey, and G. D. Armstrong
Cloned Shiga Toxin 2 B Subunit Induces Apoptosis in Ramos Burkitt's Lymphoma B Cells
Infect. Immun.,
March 1, 2002;
70(3):
1279 - 1286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-j. Lee and E. Shacter
Fas Aggregation Does Not Correlate with Fas-Mediated Apoptosis
J. Immunol.,
July 1, 2001;
167(1):
82 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Inman and M. J. Allday
Apoptosis Induced by TGF-{beta}1 in Burkitt's Lymphoma Cells Is Caspase 8 Dependent But Is Death Receptor Independent
J. Immunol.,
September 1, 2000;
165(5):
2500 - 2510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wade and M. J. Allday
Epstein-Barr Virus Suppresses a G2/M Checkpoint Activated by Genotoxins
Mol. Cell. Biol.,
February 15, 2000;
20(4):
1344 - 1360.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. G. Tepper and M. F. Seldin
Modulation of Caspase-8 and FLICE-Inhibitory Protein Expression as a Potential Mechanism of Epstein-Barr Virus Tumorigenesis in Burkitt's Lymphoma
Blood,
September 1, 1999;
94(5):
1727 - 1737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Spender, E. J. Cannell, M. Hollyoake, B. Wensing, J. M. Gawn, M. Brimmell, G. Packham, and P. J. Farrell
Control of Cell Cycle Entry and Apoptosis in B Lymphocytes Infected by Epstein-Barr Virus
J. Virol.,
June 1, 1999;
73(6):
4678 - 4688.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. I. Gutierrez, B. Cherney, A. Hussain, H. Mostowski, G. Tosato, I. Magrath, and K. Bhatia
Bax Is Frequently Compromised in Burkitt's Lymphomas with Irreversible Resistance to Fas-induced Apoptosis
Cancer Res.,
February 1, 1999;
59(3):
696 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Gronbak, P. t. Straten, E. Ralfkiaer, V. Ahrenkiel, M. K. Andersen, N. E. Hansen, J. Zeuthen, K. Hou-Jensen, and P. Guldberg
Somatic Fas Mutations in Non-Hodgkin's Lymphoma: Association With Extranodal Disease and Autoimmunity
Blood,
November 1, 1998;
92(9):
3018 - 3024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Plumas, M.-C. Jacob, L. Chaperot, J.-P. Molens, J.-J. Sotto, and J.-C. Bensa
Tumor B Cells From Non-Hodgkin's Lymphoma Are Resistant to CD95 (Fas/Apo-1)-Mediated Apoptosis
Blood,
April 15, 1998;
91(8):
2875 - 2885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Baiocchi, V. P. Khatri, M. J. Lindemann, M. E. Ross, G. Papoff, A. J. Caprio, T. V. Caprio, R. Fenstermaker, G. Ruberti, Z. P. Bernstein, et al.
Phenotypic and Functional Analysis of Fas (CD95) Expression in Primary Central Nervous System Lymphoma of Patients With Acquired Immunodeficiency Syndrome
Blood,
September 1, 1997;
90(5):
1737 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Landowski, M. C. Gleason-Guzman, and W. S. Dalton
Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis
Blood,
March 15, 1997;
89(6):
1854 - 1861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Nagata and P Golstein
The Fas death factor
Science,
March 10, 1995;
267(5203):
1449 - 1456.
[Abstract]
[PDF]
|
|
|
|
|
